



USOORE37564E

(19) **United States**
 (12) **Reissued Patent**
Spona et al.

(10) **Patent Number: US RE37,564 E**
 (45) **Date of Reissued Patent: Feb. 26, 2002**

(54) **COMPOSITION FOR CONTRACEPTION**

- (75) Inventors: **Jürgen Spona**, Vienna (AT); **Bernd Düsterberg**, Berlin (DE); **Frank Lüdicke**, Geneva (CH)
- (73) Assignee: **Schering Aktiengesellschaft**, Berlin (DE)
- (*) Notice: This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **09/503,952**
- (22) Filed: **Feb. 15, 2000**

Related U.S. Patent Documents

Reissue of:

- (64) Patent No.: **5,824,667**
 Issued: **Oct. 20, 1998**
 Appl. No.: **09/742,147**
 Filed: **Oct. 31, 1996**

U.S. Applications:

- (63) Continuation of application No. 08/268,996, filed on Jun. 30, 1994, now Pat. No. 5,583,129.

(30) **Foreign Application Priority Data**

Dec. 22, 1993 (DE) 43 44 462

- (51) **Int. Cl.⁷** **A61K 31/57; A61K 31/565**
 (52) **U.S. Cl.** **514/170**
 (58) **Field of Search** 514/170

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,129,564 A 12/1978 Wiechert et al. 260/239.57
 5,569,652 A 10/1996 Beier et al. 514/173
 5,756,490 A 5/1998 Lachnit et al. 514/170

FOREIGN PATENT DOCUMENTS

DE 30 22 337 A1 1/1982
 DE 44 11 585 A1 10/1995
 EP 0 253 607 1/1988
 EP 0 398 460 B1 11/1990
 EP 0 491 415 6/1992
 EP 0 491 438 6/1992
 EP 640 343 3/1995
 WO WO 95/26730 10/1995
 WO WO 98/04246 2/1998
 WO WO 98/04265 2/1998
 WO WO 98/04267 2/1998
 WO WO 98/04268 2/1998

OTHER PUBLICATIONS

G.B. Melis, et al., Contraception, "A Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 µg Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gest odene on Coagulatory Factors", vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract].
 A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, "Multicenter Clinical Trial on the new Oral Contraceptive Containing 20 µg Ethinylestradiol", Chapter 1, pp. 747-756, (1990).
 Parke Davis package insert for Loestrin, Jun., 1993.

W. Oelkers et al., "Journal of Clinical Endocrinology and Metabolism", p. 73, pp. 837-842, (1991).
 W. Oelkers et al., "Acta Endocrinologica", Suppl. 4, p. 71, #97, (1992) (Abstract Only).
 W. Oelkers et al., "Journal of Clinical Endocrinology and Metabolism", 80, pp. 1816-1821, (1995).
 Elstein et al., *Zentralblatt für Gynäkologie*, 117, pp. 559-565, (1995).
 Schillinger et al., "Arzneim.-Forsch.", 26, pp. 2242-2245, (Abstract only), (1976).
 Huempel et al., *Contraception*, 16, pp. 199-216 (Abstract only), (1977).
 Düsterberg et al., "Acta Obstet Gynecol Scand. Suppl.", 88, pp. 27-31, (1979).
 Leis et al., "Geburtshilfe Frauenheilkd", 39, pp. 54-57 (Abstract only), (1979).
 Klebe et al., "Arch Gynecol", 234, pp. 113-120, (Abstract only) (1983).
 Holdaway et al., "Acta Endocrinol", 109, 522-529, (Abstract only) (1985).
 Kuhl et al., "Contraception", 30, pp. 467-482, (1985).
 Larsson-Cohn et al., "Acta Obstet Gynecol Scand", 65, pp. 125-128, (Abstract only) (1986).
 Calaf-Alsina et al., "Obstet Gynecol", 69, pp. 255-258, (Abstract only) (1987).
 Spona et al., "Gynecol Obstet Invest", 23, pp. 184-193, (1987).
 Jandrain et al., "Am J. Obstet Gynecol", 163, pp. 378-381, (1990).
 Porcile et al., "Fertility and Sterility", 55, pp. 877-881, (Abstract only) (1991).
 Scheen et al., "Fertility and Sterility", 59, pp. 797-802, (Abstract only) (1993).
 Kuhnz et al., "Contraception", 48, pp. 557-575, (1993).
 M. Elstein, "Advances in Contraception", 12, pp. 155-156, (1996).
 Foidart et al., "Int'l J. Gynecol & Obstet", 46, Suppl. 3, p. 11, (1994).
 Oelkers et al., "Advances in Contraception", 7, Suppl. 3, pp. 195-206 (1991).
 Filshie and Guillebaud, eds., "Contraception: Science and Practice", 69-93 (1989).
 J. Guillebaud, *Br. J. Family Planning*, 12 (Suppl.), 35-43 (1987).
 Van Keep et al., eds. "The Controversial Climacteric", MTP Press Limited, 9-18 (1981).
 German Pharmacopeia, 9th Edition, 1986—English Translation.
 PCT Search Report dated May 12, 1995.*

* cited by examiner

Primary Examiner—Phyllis G. Spivack
 (74) Attorney, Agent, or Firm—Millen White Zelano & Branigan

(57) **ABSTRACT**

A combination product for oral contraception is disclosed comprising an estrogen selected from
 2.0 to 6.0 mg of 17β-estradiol and
 0.020 mg of ethinylestradiol;
 and a gestagen selected from
 [0.25 to 0.30] 2.5 to 3.0 mg of drospirenone and
 [0.1 to 0.2] 1 to 2 mg of cyproterone acetate,
 followed by 5 or 4 pill-free or sugar pill days.

13 Claims, 1 Drawing Sheet